Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887565 | 0.90 | SLC6A9 (0.43) | L3MBTL1KDM4ECNR2CNR1OPRK1 | |
| SCHEMBL4896093 | 0.86 | KMT2A (0.46) | L3MBTL1KDM4EOPRK1KMT2AALDH1A1 | |
| SCHEMBL4889461 | 0.85 | KDM4E (0.44) | L3MBTL1KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4892647 | 0.82 | KDM4E (0.45) | L3MBTL1KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4882730 | 0.77 | THRB (0.42) | KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4887134 | 0.73 | HPGD (0.47) | L3MBTL1KDM4EKMT2APKMALDH1A1 | |
| SCHEMBL4893181 | 0.68 | THRB (0.43) | KDM4EKMT2AALDH1A1HTTMEN1 | |
| SCHEMBL4892547 | 0.67 | ALDH1A1 (0.40) | KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL14102825 | 0.67 | CNR1 (0.40) | L3MBTL1KDM4ECNR2CNR1KMT2A | |
| SCHEMBL8675410 | 0.64 | KMT2A (0.53) | L3MBTL1CNR1OPRK1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | L3MBTL1 3221/4885KDM4E 2519/4885CNR2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.